PELUNTAMIG
UNII 4A6ZWS8R8E

Substance Identification & Data

This profile provides standardized clinical and technical data for Peluntamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 4A6ZWS8R8E.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2928515-21-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

4A6ZWS8R8E

CAS Registry Number

2928515-21-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PELUNTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C199289

National Cancer Institute reference terminology for clinical and research data.

INN ID

13261

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-161

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Peluntamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

PELUNTAMIG

Common Names & Synonyms

BISPECIFIC ANTIBODY AGAINST DLL3 AND CD47

H-GAMMA1 HEAVY CHAIN ANTI-CD47 (1-444) (VH (HOMO SAPIENS IGHV1-46*01 (88.7%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT (8.8.7) (26-33.51-58.97-103)) (1-114) -HOMO SAPIENS IGHG1*01 G1M17,1 CH1 K120, CH3 D12, L14, G1V74 CH3 C10, G1V32 CH3 W22 (KNOB) (CH1 K120 (211) (115-212), HINGE 1-15 (213-227), CH2 (228-337), CH3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), CHS (443-444)) (115-444)), (217-214')- DISULFIDE WITH COMMON L-KAPPA LIGHT CHAIN (1'-214') (V-KAPPA (HOMO SAPIENS IGKV3-20*01 (84.4%) -IGKJ1*01 (91.7%), CDR-IMGT (6.3.9) (27'-32'.50'-52'.89'-97')) (1'-107') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214'));

IMMUNOGLOBULIN G1 (350-CYSTEINE,367-SERINE,369-ALANINE,408-VALINE), ANTI-(HUMAN NOTCH LIGAND DLL3) (HUMAN-MUS MUSCULUS MONOCLONAL PT217 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PT217 .KAPPA.-CHAIN, (227->223'),(230->226'),(350->351')-TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (351-CYSTEINE,363-TRYPTOPHAN) ANTI-(HUMAN CD47 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL PT217 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PT217 .KAPPA.-CHAIN

IMMUNOGLOBULIN H-GAMMA1_L-KAPPA, ANTI-(HOMO SAPIENS CD47 (CD47 MOLECULE, INTEGRIN ASSOCIATED PROTEIN, IAP, MER6, OA3) AND ANTI-(HOMO SAPIENS DLL3 (DELTA-LIKE LIGAND 3, DELTA LIKE CANONICAL NOTCH LIGAND 3)), BISPECIFIC;

PELUNTAMIG [INN]

PELUNTAMIG [USAN]